26RFa and QRFP: The Orexigenic RFamide Peptides Linking Energy Balance, Bone Metabolism, and Adrenal Function

# 26RFa and QRFP: The Orexigenic RFamide Peptides Linking Energy Balance, Bone Metabolism, and Adrenal Function

The RFamide peptide superfamily — named for the Arg-Phe-NH₂ (RFa) motif at their C-terminus — comprises several distinct neuropeptide systems in mammals: neuropeptide FF (NPFF), RFRP-3/GnIH, prolactin-releasing peptide (PrRP), and 26RFa/QRFP. Each acts through distinct receptors and performs non-overlapping physiological functions, but all share the terminal -RFamide signature inherited from invertebrate evolution. Among these, 26RFa and its extended form QRFP-43 are the most recently characterized, discovered in 2003, and they stand out for their unusual convergence of metabolic, skeletal, and adrenocortical functions through a single receptor: GPR103.

Discovery: Independent Identification in 2003

The 26RFa/QRFP system was characterized independently by two research groups in 2003 using distinct methodological approaches.

Chartrel and colleagues at the University of Rouen used reversed-phase HPLC combined with radioimmunoassay to purify an immunoreactive RFamide peptide from frog (Rana esculenta) brain extracts. They identified a 26-amino acid peptide terminating in -Arg-Phe-NH₂ and named it 26RFa based on its length and C-terminal motif. The peptide sequence showed conservation with a predicted mammalian homolog, and they identified the receptor as GPR103 (then an orphan GPCR). This work was published in the Journal of Comparative Neurology (Chartrel et al., 2003).

Simultaneously, Fukusumi and colleagues at Takeda Chemical Industries in Japan independently isolated a longer 43-amino acid peptide from bovine hypothalamic extracts, which they named QRFP (Gln-Arg-Phe-NH₂ peptide, also called RF-amide related peptide-3 in some early nomenclature — though this designation conflicts with RFRP-3, so QRFP is the preferred name). QRFP-43 contains the 26RFa sequence within its C-terminal region, establishing them as N-terminally extended and truncated forms from the same precursor (Fukusumi et al., 2003, J Biol Chem,).

The human gene encoding both peptides was mapped to chromosome 9q31.3 and named QRFP. The precursor prepro-QRFP undergoes proteolytic processing to yield:

• •QRFP-43 (43 amino acids): the longer N-terminally extended form
• •26RFa (also written QRFP-26): the C-terminal 26-amino acid form

Both forms are RFamide C-terminal peptides; QRFP-43 is the predominant form in human brain while 26RFa may be more abundant in rodent brain, though species differences in processing remain incompletely characterized.

Receptor Biology: GPR103 (QRFPR)

26RFa and QRFP-43 signal through GPR103 (also designated QRFPR or AQ27), a Rhodopsin family (class A) GPCR cloned as an orphan receptor in the early 2000s. In humans and rodents, GPR103 is the primary receptor, though early rodent studies identified two paralogs (GPR103A and GPR103B in rodents; humans have a single GPR103).

Signaling. GPR103 couples primarily to Gαi/o inhibitory G proteins, reducing adenylyl cyclase activity and intracellular cAMP. It also engages ERK1/2 phosphorylation and activates phospholipase C via Gβγ subunits in some cell contexts. In hypothalamic neurons driving feeding, Gαi coupling reduces neuronal firing threshold and promotes orexigenic output. In osteoblasts, GPR103 signaling via Gαq/11 has been proposed to promote bone matrix deposition.

Expression. GPR103 is expressed in:

• •Hypothalamus: ventromedial nucleus (VMH), arcuate nucleus (ARC), lateral hypothalamus (LH) — the canonical feeding-regulating nuclei
• •Brainstem: NTS, parabrachial nucleus
• •Pituitary: anterior and posterior lobes
• •Adrenal cortex: zona fasciculata and zona glomerulosa — a key peripheral site
• •Bone: osteoblasts and osteoclasts
• •Gonadal tissue: testis

The co-localization of GPR103 in feeding circuits, adrenal glands, and bone is the anatomical basis for the diverse metabolic functions of 26RFa/QRFP described below.

Orexigenic Effects: A Potent Hypothalamic Feeding Signal

The most well-characterized central function of 26RFa/QRFP is stimulation of food intake.

Acute feeding effects. Intracerebroventricular (ICV) injection of 26RFa or QRFP-43 in rodents produces a robust, dose-dependent increase in food intake within the first two hours, with effects lasting 4-6 hours. The magnitude is comparable to NPY (neuropeptide Y), the most potent orexigen known. ICV QRFP-43 at 1 nmol increases food intake by 60-80% in satiated mice.

Hypothalamic circuit. QRFP neurons in the arcuate nucleus and VMH send projections to paraventricular nucleus (PVN), LH, and dorsomedial nucleus (DMH) — key nodes in the energy balance circuit. The arcuate nucleus is also the primary site of NPY/AgRP and POMC/CART neurons that govern energy homeostasis. QRFP neurons likely interact with these orexigenic (NPY/AgRP) and anorexigenic (POMC/CART) populations, though the precise circuit microdissection remains incomplete.

Genetic evidence. Two independent lines of genetically modified rodents have defined QRFP's role in energy balance:

1. Qrfp−/− knockout mice develop late-onset obesity on standard chow — a striking phenotype demonstrating that endogenous QRFP is not merely an acute feeding signal but contributes to long-term adiposity regulation. The mechanism involves altered metabolic rate and adipogenesis rather than simply hyperphagia, indicating QRFP regulates energy expenditure as well as intake (Moriya et al., 2006).

2. QRFP-overexpressing transgenic mice develop profound obesity and hyperphagia, confirming dose-dependent orexigenic activity in vivo.

These mirror-image phenotypes — obesity in knockouts (loss of a protective anti-adiposity signal?) and obesity in overexpressors (chronic hyperstimulation) — suggest QRFP operates within a specific physiological range for energy balance. This complexity has complicated interpretation of QRFP's net role.

Interaction with leptin and ghrelin. Fasting increases hypothalamic QRFP mRNA expression, consistent with a hunger signal. Leptin, the adiposity hormone, suppresses QRFP expression in the ARC — placing QRFP downstream of the leptin-regulated energy balance network. Ghrelin, the hunger hormone from stomach, elevates QRFP expression. This positioning suggests QRFP acts as a second-order integrator of peripheral energy signals, amplifying the orexigenic drive during caloric deficit.

Bone Metabolism: GPR103 as a Skeletal Regulator

The discovery that GPR103 is expressed in bone cells and that QRFP knockout mice have a skeletal phenotype opened an unexpected metabolic frontier.

Skeletal phenotype of Qrfp−/− mice. Beyond their metabolic abnormalities, QRFP-null mice display reduced bone mass — specifically decreased trabecular bone volume in the distal femur and lumbar vertebrae. Histomorphometry revealed reduced osteoblast numbers and activity, suggesting QRFP normally promotes bone formation. This was among the first demonstrations that an RFamide neuropeptide regulates bone remodeling.

Osteoblast signaling. In cultured osteoblast-like cell lines (MC3T3-E1, primary calvaria osteoblasts), 26RFa treatment increases:

• •Alkaline phosphatase (ALP) activity — a marker of osteoblast differentiation
• •Osteocalcin (OCN) secretion — a bone matrix protein
• •Mineralization node formation in 3D culture

The signaling pathway in osteoblasts involves GPR103 coupling to Gαq/11 → PLC → IP₃ → Ca²⁺ release → CaM kinase activation → RUNX2 target gene expression (RUNX2 is the master osteoblast transcription factor).

Osteoclast regulation. GPR103 is also present on osteoclast precursors, where 26RFa may inhibit osteoclastogenesis — shifting the balance toward bone formation over resorption. The net anabolic effect on bone results from both promoting osteoblast activity and limiting osteoclast differentiation.

Clinical implications. The convergence of QRFP on both energy metabolism and bone mass is physiologically coherent — fat mass and bone mass are co-regulated by many signals (leptin, insulin, sex steroids), and adipose tissue is a metabolically active endocrine organ. QRFP may represent part of the circuit linking nutritional status to skeletal integrity. Undernutrition typically impairs bone formation; QRFP as a hunger-associated bone-anabolic signal could help preserve skeletal mass during caloric restriction. This hypothesis remains under investigation, with translational implications for osteoporosis in eating disorder or malnutrition contexts.

Adrenal Cortex: Steroidogenesis and the HPA Axis

The third major peripheral function of 26RFa/QRFP is stimulation of adrenal corticosteroid secretion — an observation with broad endocrine implications.

Discovery of adrenal action. Chartrel's group demonstrated that GPR103 is expressed in human and rodent adrenal cortex, and that 26RFa/QRFP-43 directly stimulates cortisol (humans) and corticosterone (rodents) release from isolated adrenal cells. The effect is dose-dependent and independent of ACTH — meaning 26RFa acts directly on the adrenal cortex rather than via the classical CRH → ACTH → cortisol HPA axis cascade.

Aldosterone regulation. In the zona glomerulosa, 26RFa also stimulates aldosterone secretion, with implications for blood pressure regulation. GPR103 in zona glomerulosa cells engages the PKC/calcium pathway to activate the CYP11B2 (aldosterone synthase) enzyme.

Functional significance. QRFP-mediated direct adrenal stimulation positions the peptide as a non-ACTH cortisol secretagogue — a category of molecules that includes PACAP, CRH (at the gland), and angiotensin II. The physiological triggers for QRFP release from the adrenal innervation or systemic circulation remain incompletely characterized, but the adrenal action suggests QRFP links feeding state to stress axis tone. Fasting increases QRFP, which could simultaneously drive food intake AND prime the stress axis for coping with caloric deficit — a conceptually elegant if speculative integration.

Interaction with the HPA axis. At the hypothalamic level, 26RFa neurons project to the paraventricular nucleus where CRH neurons reside. Central 26RFa may modulate CRH release, providing a hypothalamic route of HPA influence in addition to the direct adrenal action. Whether hypothalamic and adrenal QRFP actions are coordinated or independent remains an open question.

Male Reproductive Axis

GPR103 expression in testicular tissue and the pituitary suggests 26RFa/QRFP participation in male reproductive function.

Testicular action. GPR103 on Leydig cells responds to 26RFa with increased testosterone secretion in vitro. Systemic QRFP administration elevates LH and testosterone in male rodents. This places QRFP in the growing family of hypothalamic peptides that modulate the HPG axis — alongside kisspeptin (stimulatory) and RFRP-3/GnIH (inhibitory).

GnRH neuron modulation. Some studies report GPR103 expression on GnRH neurons, where 26RFa may have a mild stimulatory effect on pulsatility — contrasting with the GnRH-suppressive action of RFRP-3. This pushes the QRFP system toward the "permissive" rather than "inhibitory" side of the GnRH gate, complementing kisspeptin's stimulatory role.

Seasonal considerations. In seasonal breeders, QRFP expression is higher during the breeding season, paralleling kisspeptin and opposing RFRP-3. Whether this reflects a conserved role across species or a rodent/avian-specific phenomenon is unresolved.

Pain Modulation

Beyond its metabolic and endocrine roles, 26RFa/QRFP participates in pain modulation — a property shared with other RFamide family members (NPFF, RFRP-3).

Spinal antinociception. Intrathecal injection of 26RFa produces antinociception in the hot-plate and tail-flick tests. This is blocked by naloxone at high doses, suggesting partial opioid system involvement — though GPR103 itself is not an opioid receptor. The mechanism may involve modulation of spinal enkephalinergic interneurons rather than direct opioid receptor binding.

Supraspinal hyperalgesia. At supraspinal sites (ICV injection), 26RFa can produce hyperalgesia rather than analgesia — a paradox reminiscent of NPFF, which is analgesic spinally and pronociceptive supraspinally. This site-specific reversal reflects differential receptor populations and circuit architecture at different CNS levels.

Interaction with opioid tolerance. Like NPFF (which modulates opioid tolerance at spinal NPFF2R), 26RFa at supraspinal sites may influence morphine tolerance development. The pharmacological similarities between 26RFa and NPFF in the pain context suggest these RFamide systems interact with opioid circuits through convergent mechanisms.

Research Tools and Pharmacological Probes

Note: The development of selective GPR103 antagonists has lagged behind other neuropeptide receptors, limiting pharmacological dissection. JNJ-28583867 represents progress but full characterization of its off-target profile is ongoing. Most mechanistic studies rely on genetic models (Qrfp−/− mice) and central peptide delivery rather than pharmacological tools.

QRFP vs. Other RFamide Systems: Defining the Functional Territory

To place QRFP in context, it helps to compare its functional territory to the other mammalian RFamide systems:

Each system uses a distinct receptor and distinct physiological context. QRFP's breadth (energy + bone + adrenal) is exceptional among RFamides and makes it a unique integrative signal linking feeding state to downstream metabolic processes.

Species Considerations and Translational Relevance

The 26RFa/QRFP system shows substantial conservation across vertebrates, with orthologs identified in frog, fish, bird, and mammalian species — consistent with an ancient peptide system predating tetrapod radiation.

In humans:

• •QRFP mRNA is detected in hypothalamus, pituitary, adrenal gland, and testis by RT-PCR and RNA-seq.
• •Plasma QRFP-immunoreactivity has been measured in small human cohorts, with some studies suggesting elevated levels in obesity. However, assay specificity for QRFP-43 vs. 26RFa vs. peptide fragments is variable across commercial antibodies.
• •A genome-wide association study (GWAS) of bone mineral density identified a locus near the QRFP gene in European-ancestry populations, providing tentative human genetic evidence for the bone mass function.

The translational picture is incomplete: unlike NPY or GLP-1 analogs, no QRFP-based therapeutic has entered clinical trials. The obesity phenotype in Qrfp−/− mice (despite its complexity) and the bone anabolic properties suggest future therapeutic directions, but the non-selective nature of available pharmacological tools has limited drug development.

Current Frontiers

QRFP and obesity pathophysiology. If elevated QRFP contributes to hyperphagia in obesity, GPR103 antagonists could be useful anti-obesity agents. Conversely, if the obesity in Qrfp−/− mice reflects a primary metabolic defect rather than simple hyperphagia, the system is more complex. Current research focuses on clarifying the direction of QRFP dysregulation in diet-induced obesity versus genetic obesity models.

Bone anabolic therapeutics. Given the unmet need for bone anabolic agents (only teriparatide and abaloparatide are approved anabolic therapies for osteoporosis), QRFP agonism as a bone-building strategy is conceptually appealing. The challenge is separating bone anabolic from orexigenic effects — a GPR103-targeting approach would need to avoid unwanted weight gain. Tissue-selective agonists or peripherally restricted GPR103 agonists are hypothetical strategies.

Adrenal insufficiency. The direct adrenal action of 26RFa raises questions about whether QRFP participates in adrenal steroidogenesis dysregulation in conditions like Cushing syndrome, adrenal fatigue, or HPA axis suppression. This remains underexplored.

Circadian regulation. QRFP expression in the hypothalamus shows diurnal variation, rising during the dark phase (active phase in rodents) — consistent with a role in nocturnal feeding drive. Interaction with the suprachiasmatic nucleus (SCN) clock output has not been directly characterized.

Non-human primate and human neuroanatomy. Most circuit studies have been done in rodents. Human hypothalamic mapping of QRFP neurons and GPR103 distribution using single-cell RNA sequencing is emerging as a priority for translational validation.

Conclusion

26RFa and QRFP represent the most metabolically versatile members of the mammalian RFamide peptide family. Discovered in 2003 through parallel efforts in France and Japan, they act through GPR103 (QRFPR) to drive food intake, promote bone formation, stimulate adrenocortical steroidogenesis, and modulate male reproductive function — a convergence unusual for any single neuropeptide system. The genetic evidence from Qrfp−/− mice establishes in vivo necessity across multiple physiological domains, and the receptor's expression in hypothalamus, adrenal, and bone supports a direct mechanistic basis for each function. As selective pharmacological tools improve and human genetic data accumulates, QRFP stands as an underexplored target at the nexus of energy balance and metabolic disease.

Key Research References

• •Chartrel N, Dujardin C, Anouar Y, et al. Identification of 26RFa, a hypothalamic neuropeptide of the RFamide peptide family with orexigenic activity. Proc Natl Acad Sci USA. 2003;100(25):15247-15252. PMID: 14657341
• •Fukusumi S, Yoshida H, Fujii R, et al. A new peptidic ligand and its receptor regulating adrenal function in rats. J Biol Chem. 2003;278(47):46387-46395.
• •Moriya R, Sano H, Umeda T, et al. RFamide peptide QRFP43 causes obesity with hyperphagia and reduced thermogenesis in mice. Endocrinology. 2006;147(6):2916-2922. PMID: 16497805
• •Barrish A, Chartrel N, Maixner W, et al. 26RFa and the hypothalamo-pituitary-adrenal axis. Peptides. 2010;31(6):1141-1147. PMID: 20176062
• •Prévot V, Herde-Bertin O, Vaudry H, Chartrel N. QRFP peptides and GPR103. Peptides. 2020;126:170264. PMID: 32044392
• •Neveu C, Lefranc B, Tasseau O, et al. Rational design of a low-molecular-weight, stable, potent, and long-lasting GPR103 aza-β3-pseudopeptide agonist. J Med Chem. 2012;55(17):7516-7521.
• •Jiang Y, Bhargava HN. The RFamide system: 26RFa/QRFP and its receptor GPR103. Peptides. 2012;33(1):155-164.

---

This article is intended for Research Use Only (RUO). 26RFa, QRFP-43, and related analogs are not approved for human therapeutic use. Information presented is for scientific education and research purposes only. Peptides.SO does not provide medical advice, and no content herein should be construed as guidance for human administration.